Although the phosphodiesterase inhibitors have revolutionised the treatment of ED, postoperative ED due to nerve damage remains a therapeutic challenge.
Michel
Martin C
MC
Department of Pharmacology & Pharmacotherapy, University of Amsterdam, The Netherlands. m.c.michel@amc.nl
D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism*; D007172:Erectile Dysfunction / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D005726:Ganglia, Parasympathetic / Q000378:metabolism*; D053613:Janus Kinase 1; D053612:Janus Kinases / Q000378:metabolism*; D008297:Male; D009416:Nerve Regeneration; D010413:Penis / Q000294:innervation* / Q000378:metabolism* / Q000601:surgery; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D050791:STAT Transcription Factors / Q000378:metabolism*; D015398:Signal Transduction; D015854:Up-Regulation
D019208:Brain-Derived Neurotrophic Factor; D010726:Phosphodiesterase Inhibitors; D050791:STAT Transcription Factors; C507906:Jak1 protein, rat; D053613:Janus Kinase 1; D053612:Janus Kinases